27th Oct 2025 08:52
(Alliance News) - GSK PLC on Monday announced an agreement with Syndivia that grants GSK exclusive worldwide rights to develop and commercialise a preclinical antibody-drug conjugate for metastatic castration-resistant prostate cancer.
The London-based pharmaceutical company said the drug has shown "enhanced anti-tumour activity" and an "encouraging safety profile" which demonstrates "best-in-class potential".
In preclinical studies, the antibody-drug conjugate was effective at shrinking tumours without causing a "proportional increase" in significant side effects.
Syndivia is a Strasbourg, France-based private biotechnology company focused on "next-generation" ADCs.
Under the agreement with GSK, Syndivia will receive an upfront payment as well as success-based development and commercial milestone payments up to a total of GBP268 million.
Syndivia also will receive from GSK tiered royalties on future product sales worldwide.
Hesham Abdullah, global head of Oncology R&D at GSK, said: "Prostate cancer represents a significant health burden and an emerging area of growth for GSK, where targeted therapies are urgently needed in metastatic castration-resistant settings. The addition of this ADC builds on GSK's growing portfolio and strengths in tumour-targeted technologies."
GSK shares were 1.2% higher at 1,639.50 pence each on Monday morning in London.
By Tom Budszus, Alliance News slot editor
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Glaxosmithkline